Sawaki et al. reported in a randomized controlled trial (N-SAS BC07/RESPECT) that trastuzumab monotherapy could be an option as an adjuvant therapy for elderly (70–80 years) HER2+ breast cancer patients in light of less toxicity and a better quality of life compared with chemotherapy plus trastuzumab [29]. This evidence concerns the gene ERBB2 and breast cancer.